Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05994053 · ClinicalTrials.gov registry record · NA
Neuromodulation for a Novel OCD Biomarker and Treatment
A NA study of OCD, sponsored by Boston University Charles River Campus.
- Recruiting
- Registry status
- NA
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT05994053: Recruiting NA study of OCD, sponsored by Boston University Charles River Campus.
NCT05994053 is a NA study of OCD that is actively recruiting participants, run by Boston University Charles River Campus. The registered enrollment target is 90 participants, below the 813-participant average among 18 other OCD trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05994053, a NA study of OCD, is actively recruiting participants, sponsored by Boston University Charles River Campus.
- RECRUITING
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
Although multiple treatments for OCD exist, slow symptom decrease, high remission, and significant side effects for some OCD patients limit their efficacy. More research into the precise neural mechanisms and linked cognitive functions in OCD is also necessary. To address both concerns, this study by Dr. Reinhart and his team will test a new, non-invasive, and well-tolerated neuromodulation method for reducing OCD symptoms, based on reward-related rhythms of the orbitofrontal cortex (OFC; a brain region responsible for reward, decision making and other crucial functions that is affected by OCD). This proposal is based on highly encouraging preliminary data in both subsyndromal and treatment-resistant populations that shows rapid reductions in OCD behaviors that last at least 1-3 months. Using high-definition transcranial alternating current stimulation (HD-tACS) guided by EEG brain wave recordings, the study will test whether repetitive modulation of relevant rhythm activity in the OFC can lead to rapid (within five days) and sustainable (up to three months) OCD symptom reduction. This research aims to increase knowledge of OCD and development of effective treatment with minimal side effects.
Primary Outcome
There are 10 YBOCS questions scored 0 to 4. The total Y-BOCS score is the sum of items 1-10. A higher score is worse.
Conditions Studied
Interventions
- DEVICE high definition transcranial alternating current stimulation
Study Locations (1)
Massachusetts
- Boston University Center for Anxiety and Related Disorders (BU-CARD) - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-07-01 |
| Est. Completion | 2026-08-31 |
| Phase | NA |
What NCT05994053 shows while recruiting
NCT05994053 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 813-participant average among 18 other OCD trials with a reported enrollment target (89% lower).
The record links to 1 condition, with OCD appearing as the primary indexed condition, and to 1 intervention - of which high definition transcranial alternating current stimulation is the first listed.
NCT05994053 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05994053 about?
NCT05994053 is a clinical study titled "Neuromodulation for a Novel OCD Biomarker and Treatment". Although multiple treatments for OCD exist, slow symptom decrease, high remission, and significant side effects for some OCD patients limit their efficacy. More research into the precise neural mechanisms and linked cognitive functions in OCD is also necessary. To address both concerns, this study b...
What is the current status of trial NCT05994053?
This trial is currently recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2024-07-01. Estimated completion is 2026-08-31.
What conditions does trial NCT05994053 study?
This clinical trial studies the following conditions: OCD.
What interventions are being tested in trial NCT05994053?
The interventions under investigation include: high definition transcranial alternating current stimulation (DEVICE).
Who is sponsoring clinical trial NCT05994053?
This trial is sponsored by Boston University Charles River Campus, which has 104 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05994053 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for OCD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05994053's enrollment target sits among peer trials
90 9th of 18 higher than 10 of 18 other OCD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other OCD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Personalized DBS for OCD Guided by Stereoencephalography Mapping
RECRUITING · NA
-
Neurostimulation Versus Therapy for Problems With Emotions
RECRUITING · NA
-
How Hormones and Exposure and Response Prevention (EX/RP) Affect the Brain of People With OCD
RECRUITING · NA
-
Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings
RECRUITING · NA
-
Multi-session, Personalized Cognitive Bias Modification for Thought-Action-Fusion
RECRUITING · NA
-
Accelerated TMS for Depression and OCD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI